StockNews.com Upgrades Delcath Systems (NASDAQ:DCTH) to “Hold”

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH) from a sell rating to a hold rating in a research report released on Wednesday.

DCTH has been the topic of a number of other reports. Stephens reissued an overweight rating and set a $25.00 price target on shares of Delcath Systems in a research report on Tuesday, August 6th. HC Wainwright reissued a buy rating and set a $22.00 price target on shares of Delcath Systems in a research report on Tuesday, August 6th. Finally, Craig Hallum initiated coverage on shares of Delcath Systems in a research report on Friday, June 28th. They set a buy rating and a $18.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Delcath Systems has an average rating of Moderate Buy and a consensus target price of $19.83.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $7.78 on Wednesday. Delcath Systems has a 52-week low of $2.25 and a 52-week high of $9.18. The stock has a market cap of $216.18 million, a PE ratio of -2.94 and a beta of 0.64. The firm’s 50 day moving average price is $7.88 and its two-hundred day moving average price is $6.08.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. During the same period in the prior year, the business earned ($0.58) earnings per share. As a group, sell-side analysts predict that Delcath Systems will post -1.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors have recently added to or reduced their stakes in DCTH. Rosalind Advisors Inc. increased its stake in Delcath Systems by 155.1% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock valued at $22,184,000 after buying an additional 1,611,561 shares during the last quarter. AIGH Capital Management LLC acquired a new stake in Delcath Systems in the 4th quarter valued at $4,918,000. Vivo Capital LLC increased its stake in Delcath Systems by 94.9% in the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock valued at $7,950,000 after buying an additional 811,555 shares during the last quarter. Worth Venture Partners LLC acquired a new stake in Delcath Systems in the 4th quarter valued at $1,224,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Delcath Systems in the 4th quarter valued at $962,000. 61.12% of the stock is owned by institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.